Akari Therapeutics PLC (AKTX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $15.54M
Last updated: Nov 17, 2026 at 4:10 PM ET
Akari Therapeutics PLC (AKTX) Stock Chart
Akari Therapeutics (AKTX) has a latest price of $5.70 on Nov 17, 2026, 80.6% below its 52-week high of $29.32. Its price fell 73.1% over the past 12 months. The month-end price fell 99.9% over the 10 years through Oct 2026, a compound annual decline of 49.4%.
Price Chart
From Oct 2016 to Oct 2026, its highest month-end close was $11,992.00 in Apr 2017 and its lowest $5.15 in Mar 2026, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart AKTX with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for AKTX.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 27.8%, and over 6 months it rose 52.4%. The month-end price fell 94.0% over the 3 years through Oct 2026, a compound annual decline of 60.8%.
| Period | Change |
|---|---|
| 1 month | -42.4% |
| 3 months | -27.8% |
| 6 months | +52.4% |
| 12 months | -73.1% |
| 12 months, with dividends | -73.1% |
| Period | Change | Per year |
|---|---|---|
| 3 years | -94.0% | -60.8% |
| 5 years | -99.4% | -63.8% |
| 10 years | -99.9% | -49.4% |
Price by Year
Its best calendar year was 2019, when the price rose 11.5%, and its weakest was 2025, when it fell 76.3%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $8.24 | -28.7% |
| 2025 | $11.56 | -76.3% |
| 2024 | $48.80 | -60.9% |
| 2023 | $124.80 | -66.8% |
| 2022 | $375.92 | -68.7% |
| 2021 | $1,200.00 | -18.9% |
| 2020 | $1,480.00 | +5.7% |
| 2019 | $1,400.00 | +11.5% |
| 2018 | $1,256.00 | -63.7% |
| 2017 | $3,464.00 | -38.5% |
Trading Range
The price is 34.7% below its 50-day average of $8.72 and 35.8% below its 200-day average of $8.88.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $5.70 | |
| 52-week high | $29.32 | -80.6% |
| 52-week low | $3.02 | +89.1% |
| 50-day average | $8.72 | -34.7% |
| 200-day average | $8.88 | -35.8% |
Price Risk
Over 3 years, its largest fall from a peak was 98.2%.
| Measure | Value |
|---|---|
| 1-year beta | 2.33 |
| Largest fall, 1 year | -85.6% |
| Largest fall, 3 years | -98.2% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About AKTX
What is AKTX's 1-year price change?
Akari Therapeutics's price fell 73.1% over the past 12 months. With dividends included, the 12-month total return was -73.1%.
What is AKTX's 5-year price change?
Akari Therapeutics's month-end price fell 99.4% over the 5 years through Oct 2026, a compound annual decline of 63.8%. These figures leave out dividends.
What is AKTX's 52-week high and low?
Akari Therapeutics's 52-week high is $29.32 and its 52-week low is $3.02. Its latest price of $5.70 on Nov 17, 2026 is 80.6% below the high.
What is AKTX's beta?
Akari Therapeutics's 1-year beta against the S&P 500 is 2.33, so its price has moved more than the market over the past year. Its largest fall from a peak over the past year was 85.6%.
Is the AKTX chart free?
Yes. Advanced Charting for AKTX is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
AKTX pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors